Video

Relapse in Multiple Myeloma: Biochemical and Chemical

Author(s):

Sagar Lonial, MD,Amrita Krishnan, MD

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Related Videos
Shaji Kumar, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Douglas W. Sborov, MD, MS
Related Content
OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
November 25th 2024

FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Multiple myeloma Image credit: LASZLO – stock.adobe.com
November 15th 2024

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma